Nitric oxide synthase gene therapy: Progress and prospects

Expert Opinion on Biological Therapy

Volumn 9, Issue 7, 2009, Pages 867-878

  O'Connor, Deirdre M ^a   O'Brien, Timothy ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Cardiovascular disease; Gene therapy; Nitric oxide; Nitric oxide synthase

Indexed keywords

ADENOVIRUS VECTOR; ANGIOPOIETIN 1; BRADYKININ; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPLEX; LIPOSOME; MANGANESE SUPEROXIDE DISMUTASE; NEURONAL NITRIC OXIDE SYNTHASE; PLASMID DNA; SILDENAFIL; SUPEROXIDE DISMUTASE; TEMPOL; VASCULOTROPIN; VIRUS VECTOR;

ADVENTITIA; ANGIOGENESIS; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; BARE METAL STENT; BLOOD VESSEL WALL; BRAIN VASOSPASM; CARDIOVASCULAR DISEASE; CORONARY ARTERY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY OBSTRUCTION; DISEASE MODEL; DNA MODIFICATION; DRUG EFFECT; DRUG ELUTING STENT; DRUG INHIBITION; DRUG POTENTIATION; ENZYME SYNTHESIS; EPITHELIUM HYPERPLASIA; ERECTILE DYSFUNCTION; EX VIVO STUDY; GENE EXPRESSION; GENE TARGETING; GENE TRANSFER; GRAFT FAILURE; HEART INFARCTION; HEART INFARCTION SIZE; HEART PROTECTION; IN VIVO STUDY; INTIMA; LIMB ISCHEMIA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PARAINFLUENZA VIRUS 1; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PULMONARY HYPERTENSION; RESTENOSIS; REVIEW; SENDAI VIRUS; SUBARACHNOID HEMORRHAGE; SUSTAINED DRUG RELEASE; TARGET CELL; TRANSGENE; TREATMENT OUTCOME; VEIN BLOOD FLOW; VEIN GRAFT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS GENOME; VIRUS REPLICATION; WOUND HEALING;

ANIMALS; CARDIOVASCULAR DISEASES; ERECTILE DYSFUNCTION; GENE THERAPY; HUMANS; HYPERTENSION, PULMONARY; MALE; NITRIC OXIDE SYNTHASE; SUBARACHNOID HEMORRHAGE; VASOSPASM, INTRACRANIAL; WOUND HEALING;

ANIMALIA;

EID: 67650391207     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590903002047     Document Type: Review

References (107)

1. Ignarro LlJ, Buga GM, Wood KS, et al. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987;84(24):9265-9269
2. Moncada S, Radomski MW, Palmer RM. Endothelium-derived relaxing factor. Identification as nitric oxide and role in the control of vascular tone and platelet function. Biochem Pharmacol 1988;37(13):2495-2501
3. Yetik-Anacak G, Catravas JD. Nitric oxide and the endothelium: history and impact on cardiovascular disease. Vascul Pharmacol 2006;45(5):268-276 (Pubitemid 44765289)
4. Michel T, Feron O. Nitric oxide synthases: which, where, how, and why? J Clin Invest 1997;100(9):2146-2152
5. Bredt DS, Snyder SH. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc Natl Acad Sci USA 1990;87(2):682-685 (Pubitemid 20051434)
6. Hevel JM, White KA, Marletta MA. Purification of the inducible murine macrophage nitric oxide synthase. Identification as a flavoprotein. J Biol Chem 1991;266(34):22789-22791 (Pubitemid 21908718)
7. Pollock JS, Förstermann U, Mitchell JA, et al. Purification and characterization of particulate endothelium-derived relaxing factor synthase from cultured and native bovine aortic endothelial cells. Proc Natl Acad Sci USA 1991;88(23):10480-10484 (Pubitemid 21915859)
8. Ortiz de Montellano PR, Nishida C, Rodriguez-Crespo I, Gerber N. Nitric oxide synthase structure and electron transfer. Drug Metab Dispos 1998;26(12):1185-1189 (Pubitemid 29028637)
9. Fulton D, Gratton JP, McCabe TJ, et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999;399(6736):597- 601 • Shows a phosphorylated eNOS produces more NO and is less prone to superoxide production.
10. Sessa WC. eNOS at a glance. J Cell Sci 2004;117(Pt 12):2427-2429
11. Cosentino F, Patton S, d'Uscio LlV, et al. Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats. J Clin Invest 1998;101(7):1530-1537 (Pubitemid 28166851)
12. Cosentino F, Hürlimann D, Delli Gatti C, et al. Chronic treatment with tetrahydrobiopterin reverses endothelial dysfunction and oxidative stress in hypercholesterolaemia. Heart 2008;94(4):487-492
13. Pearce CG, Najjar SF, Kapadia MR, et al. Beneficial effect of a short-acting NO donor for the prevention of neointimal hyperplasia. Free Radic Biol Med 2008;44(1):73-81
14. Chaux A, Ruan XM, Fishbein MC, et al. Perivascular delivery of a nitric oxide donor inhibits neointimal hyperplasia in vein grafts implanted in the arterial circulation. J Thorac Cardiovasc Surg 1998;115(3):604-12; discussion 612-614 (Pubitemid 28158077)
15. Guidance for FDA Reviewers and Sponsors. Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications. Food and Drug Administration. Available from: http://www.fda.gov/cber/guidelines.htm. 2008 [Llast accessed 5 May 2009]
16. Mercier GT, Campbell JA, Chappell JD, et al. A chimeric adenovirus vector encoding reovirus attachment protein sigma1 targets cells expressing junctional adhesion molecule 1. Proc Natl Acad Sci USA 2004;101(16):6188-6193
17. Pereboev AV, Nagle JM, Shakhmatov MA, et al. Enhanced gene transfer to mouse dendritic cells using adenoviral vectors coated with a novel adapter molecule. Mol Ther 2004;9(5):712-720
18. Campos SK, Barry MA. Comparison of adenovirus fiber, protein IX, and hexon capsomeres as scaffolds for vector purification and cell targeting. Virology 2006;349(2):453-462 (Pubitemid 43782873)
19. Korokhov N, Mikheeva G, Krendelshchikov A, et al. Targeting of adenovirus via genetic modification of the viral capsid combined with a protein bridge. J Virol 2003;77(24):12931-12940 (Pubitemid 37494288)
20. L lanciotti J, Song A, Doukas J, et al. Targeting adenoviral vectors using heterofunctional polyethylene glycol FGF2 conjugates. Mol Ther 2003;8(1):99-107
21. Yang Q, Mamounas M, Yu G, et al. Development of novel cell surface CD34-targeted recombinant adenoassociated virus vectors for gene therapy. Hum Gene Ther 1998;9(13):1929-1937
22. Hedley SJ, Auf der Maur A, Hohn S, et al. An adenovirus vector with a chimeric fiber incorporating stabilized single chain antibody achieves targeted gene delivery. Gene Ther 2006;13(1):88-94
23. Nicklin SA, Reynolds PN, Brosnan MJ, et al. Analysis of cell-specific promoters for viral gene therapy targeted at the vascular endothelium. Hypertension 2001;38(1):65-70 (Pubitemid 34224772)
24. Reynolds PN, Nicklin SA, Kaliberova L, et al. Combined transductional and transcriptional targeting improves the specificity of transgene expression invivo. Nat Biotechnol 2001;19(9):838-842 (Pubitemid 32816753)
25. Wen S, Graf S, Massey PG, Dichek DA. Improved vascular gene transfer with a helper-dependent adenoviral vector. Circulation 2004;110(11):1484-1491 ••Helper-dependant adenovirus improved gene transfer to the vasculature.
26. Sharif F, Hynes SO, McMahon J, et al. Gene-eluting stents: comparison of adenoviral and adeno- associated viral gene delivery to the blood vessel wall invivo. Hum Gene Ther 2006;17(7):741-750 (Pubitemid 44100719)
27. Cable DG, Pompili VJ, O'Brien T, Schaff HV. Recombinant gene transfer of endothelial nitric oxide synthase augments coronary artery relaxations during hypoxia. Circulation 1999;100(19 Suppl):II335-9 (Pubitemid 29523556)
28. Teupe C, Richter S, Fisslthaler B, et al. Vascular gene transfer of phosphomimetic endothelial nitric oxide synthase (S1177D) using ultrasound-enhanced destruction of plasmid-loaded microbubbles improves vasoreactivity. Circulation 2002;105(9):1104-1109
29. Cable DG, O'Brien T, Kullo IJ, et al. Expression and function of a recombinant endothelial nitric oxide synthase gene in porcine coronary arteries. Cardiovasc Res 1997;35(3):553-559
30. Cable DG, Caccitolo JA, Caplice N, et al. The role of gene therapy for intimal hyperplasia of bypass grafts. Circulation 1999;100(19 Suppl):II392-6• Shows AdeNOS delivery to healthy vessels increases NO production and vascular tone.
31. Kullo IJ, Mozes G, Schwartz RS, et al. Adventitial gene transfer of recombinant endothelial nitric oxide synthase to rabbit carotid arteries alters vascular reactivity. Circulation 1997;96(7):2254-61• Shows AdeNOS delivery to healthy vessels increases NO production and vascular tone.
32. Kullo IJ, Mozes G, Schwartz RS, et al. Enhanced endothelium-dependent relaxations after gene transfer of recombinant endothelial nitric oxide synthase to rabbit carotid arteries. Hypertension 1997;30(3 Pt 1):314-320
33. Serruys PW, Lluijten HE, Beatt KJ, et al. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation 1988;77(2):361-371
34. liu MW, Roubin GS, King SB 3rd. Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia. Circulation 1989;79(6):1374-1387
35. Hayashi T, Sumi D, Juliet PA, et al. Gene transfer of endothelial NO synthase, but not eNOS plus inducible NOS, regressed atherosclerosis in rabbits. Cardiovasc Res 2004;61(2):339-351 (Pubitemid 38091774)
36. Jagadeesha DK, Miller FJ Jr, Bhalla RC. Inhibition of apoptotic signaling and neointimal hyperplasia by tempol and nitric oxide synthase following vascular injury. J Vasc Res 2008;46(2):109-118
37. von der leyen HE, Gibbons GH, Morishita R, et al. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA 1995;92(4):1137-1141
38. Janssens S, Flaherty D, Nong Z, et al. Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats. Circulation 1998;97(13):1274-1281 (Pubitemid 28169180)
39. Varenne O, Pislaru S, Gillijns H, et al. local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigs. Circulation 1998;98(9):919-926 (Pubitemid 28397443)
40. Cooney R, Hynes SO, Sharif F, et al. Effect of gene delivery of NOS isoforms on intimal hyperplasia and endothelial regeneration after balloon injury. Gene Ther 2007;14(5):396-404 (Pubitemid 46306540)
41. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346(23):1773-1780 (Pubitemid 34586912)
42. Sousa JE, Costa MA, Sousa AG, et al. Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation 2003;107(3):381-383 (Pubitemid 36158039)
43. Wang K, Kessler PD, Zhou Z, et al. local adenoviral-mediated inducible nitric oxide synthase gene transfer inhibits neointimal formation in the porcine coronary stented model. Mol Ther 2003;7(5 Pt 1):597-603 (Pubitemid 36626239)
44. Muhs A, Heublein B, Schletter J, et al. Preclinical evaluation of inducible nitric oxide synthase lipoplex gene therapy for inhibition of stent-induced vascular neointimal lesion formation. Hum Gene Ther 2003;14(4):375-383 (Pubitemid 36308356)
45. Sharif F, Hynes SO, Cooney R, et al. Gene-eluting stents: adenovirus-mediated delivery of eNOS to the blood vessel wall accelerates re-endothelialization and inhibits restenosis. Mol Ther 2008;16(10):1674-1680 •• Gene transfer of eNOS found to promote re-endothelisation in damaged vessel.
46. Fishbein I, Alferiev I, Bakay M, et al. local delivery of gene vectors from bare-metal stents by use of a biodegradable synthetic complex inhibits in-stent restenosis in rat carotid arteries. Circulation 2008;117(16):2096-2103 (Pubitemid 351572181)
47. Bolli R. The late phase of preconditioning. Circ Res 2000;87(11):972-983
48. Xi l, Kukreja RC. Pivotal role of nitric oxide in delayed pharmacological preconditioning against myocardial infarction. Toxicology 2000;155(1-3):37-44
49. Baxter GF, Ferdinandy P. Delayed preconditioning of myocardium: current perspectives. Basic Res Cardiol 2001;96(4):329-344 (Pubitemid 32700570)
50. Li Q, Guo Y, Tan W, et al. Cardioprotection afforded by inducible nitric oxide synthase gene therapy is mediated by cyclooxygenase-2 via a nuclear factor-êB dependent pathway. Circulation 2007;116(14):1577-1584
51. Li Q, Guo Y, Tan W, et al. Gene therapy with iNOS provides long-term protection against myocardial infarction without adverse functional consequences. Am J Physiol Heart Circ Physiol 2006;290(2):H584-9
52. Dawson TA, Li D, Woodward T, et al. Cardiac cholinergic NO-cGMP signaling following acute myocardial infarction and nNOS gene transfer. Am J Physiol Heart Circ Physiol 2008;295(3):H990-8
53. Smith RS Jr, Agata J, Xia CF, et al. Human endothelial nitric oxide synthase gene delivery protects against cardiac remodeling and reduces oxidative stress after myocardial infarction. Life Sci 2005;76(21):2457-2471
54. Kupatt C, Hinkel R, von Brühl Ml, et al. Endothelial nitric oxide synthase overexpression provides a functionally relevant angiogenic switch in hibernating pig myocardium. J Am Coll Cardiol 2007;49(14):1575-1584 (Pubitemid 46517952)
55. Wong AP, Nili N, Jackson ZS, et al. Expansive remodeling in venous bypass grafts: novel implications for vein graft disease. Atherosclerosis 2008;196(2):580-589
56. Sasaki Y, Suehiro S, Becker AE, et al. Role of endothelial cell denudation and smooth muscle cell dedifferentiation in neointimal formation of human vein grafts after coronary artery bypass grafting: therapeutic implications. Heart 2000;83(1):69-75 (Pubitemid 30307643)
57. West NE, Qian H, Guzik TJ, et al. Nitric oxide synthase (nNOS) gene transfer modifies venous bypass graft remodeling: effects on vascular smooth muscle cell differentiation and superoxide production. Circulation 2001;104(13):1526-1532 (Pubitemid 32917346)
58. Ohta S, Komori K, Yonemitsu Y, et al. Intraluminal gene transfer of endothelial cell-nitric oxide synthase suppresses intimal hyperplasia of vein grafts in cholesterol-fed rabbit: a limited biological effect as a result of the loss of medial smooth muscle cells. Surgery 2002;131(6):644-653 (Pubitemid 34666766)
59. Pfeiffer T, Wallich M, Sandmann W, et al. lipoplex gene transfer of inducible nitric oxide synthase inhibits the reactive intimal hyperplasia after expanded polytetrafluoroethylene bypass grafting. J Vasc Surg 2006;43(5):1021-1027
60. Yla-Herttuala S, Markkanen JE, Rissanen TT. Gene therapy for ischemic cardiovascular diseases: some lessons learned from the first clinical trials. Trends Cardiovasc Med 2004;14(8):295-300 (Pubitemid 41110607)
61. Smith RS Jr, Lin KF, Agata J, et al. Human endothelial nitric oxide synthase gene delivery promotes angiogenesis in a rat model of hindlimb ischemia. Arterioscler Thromb Vasc Biol 2002;22(8):1279-1285
62. Namba T, Koike H, Murakami K, et al. Angiogenesis induced by endothelial nitric oxide synthase gene through vascular endothelial growth factor expression in a rat hindlimb ischemia model. Circulation 2003;108(18):2250-2257 (Pubitemid 37363043)
63. Qian HS, Liu P, Huw LY, et al. Effective treatment of vascular endothelial growth factor refractory hindlimb ischemia by a mutant endothelial nitric oxide synthase gene. Gene Ther 2006;13(18):1342-1350
64. Benest AV, Stone OA, Miller WH, et al. Arteriolar genesis and angiogenesis induced by endothelial nitric oxide synthase overexpression results in a mature vasculature. Arterioscler Thromb Vasc Biol 2008;28(8):1462-1468
65. Khurana VG, Katusic ZS. Gene transfer for cerebrovascular disease. Curr Cardiol Rep 2001;3(1):10-16
66. Chen AF, O'Brien T, Tsutsui M, et al. Expression and function of recombinant endothelial nitric oxide synthase gene in canine basilar artery. Circ Res 1997;80(3):327-335 (Pubitemid 27093346)
67. Tsutsui M, Chen AF, O'Brien T, et al. Adventitial expression of recombinant eNOS gene restores NO production in arteries without endothelium. Arterioscler Thromb Vasc Biol 1998;18(8):1231-1241 (Pubitemid 28376179)
68. Onoue H, Tsutsui M, Smith l, et al. Expression and function of recombinant endothelial nitric oxide synthase gene in canine basilar artery after experimental subarachnoid hemorrhage. Stroke 1998;29(9):1959-65; discussion 1965-1966
69. Tsutsui M, Onoue H, Iida Y, et al. Effects of recombinant eNOS gene expression on reactivity of small cerebral arteries. Am J Physiol Heart Circ Physiol 2000;278(2):H420-7 (Pubitemid 30131240)
70. Akiyama M, Eguchi D, Weiler D, et al. Expression and function of recombinant S1179D endothelial nitric oxide synthase in canine cerebral arteries. Stroke 2002;33(4):1071-1076 (Pubitemid 34293594)
71. Khurana VG, Smith lA, Weiler DA, et al. Adenovirus-mediated gene transfer to human cerebral arteries. J Cereb Blood Flow Metab 2000;20(9):1360-1371
72. Chen AF, O'Brien T, Katusic ZS. Transfer and expression of recombinant nitric oxide synthase genes in the cardiovascular system. Trends Pharmacol Sci 1998;19(7):276-286 (Pubitemid 28358087)
73. Khurana VG, Smith lA, Baker TA, et al. Protective vasomotor effects of in vivo recombinant endothelial nitric oxide synthase gene expression in a canine model of cerebral vasospasm. Stroke 2002;33(3):782-789
74. Meyrick B, Reid l. The effect of chronic hypoxia on pulmonary arteries in young rats. Exp lung Res 1981;2(4):257-271
75. Reid lM. lung growth in health and disease. Br J Dis Chest 1984;78(2):113-134 (Pubitemid 14167833)
76. Coggins MP, Bloch KD. Nitric oxide in the pulmonary vasculature. Arterioscler Thromb Vasc Biol 2007;27(9):1877-1885
77. Janssens SP, Bloch KD, Nong Z, et al. Adenoviral-mediated transfer of the human endothelial nitric oxide synthase gene reduces acute hypoxic pulmonary vasoconstriction in rats. J Clin Invest 1996;98(2):317-324 (Pubitemid 26255729)
78. Budts W, Pokreisz P, Nong Z, et al. Aerosol gene transfer with inducible nitric oxide synthase reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling in rats. Circulation 2000;102(23):2880-2885 (Pubitemid 30954326)
79. Jiang l, Quarck R, Janssens S, et al. Effect of adenovirus-mediated gene transfer of nitric oxide synthase on vascular reactivity of rat isolated pulmonary arteries. Pflugers Arch 2006;452(2):213-221
80. Zhao YD, Courtman DW, Deng Y, et al. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ Res 2005;96(4):442-450 (Pubitemid 40354538)
81. Pulmonary Hypertension: Assessment of Cell Therapy (PHACeT). NCT00469027 US National Institute for Health. Available from: http://www.clinicaltrials.gov/ ct2/ show/NCT00469027?term = nct00469027&rank = 1 [last updated 8 January 2009] [last accessed 5 May 2009]
82. Kanki-Horimoto S, Horimoto H, Mieno S, et al. Implantation of mesenchymal stem cells overexpressing endothelial nitric oxide synthase improves right ventricular impairments caused by pulmonary hypertension. Circulation 2006;114(Suppl 1):I181-5 (Pubitemid 44297148)
83. Zhang F, Wu S, Lu X, et al. Gene transfer of endothelial nitric oxide synthase attenuates flow-induced pulmonary hypertension in rabbits. Ann Thorac Surg 2008;85(2):581-585
84. Frank S, Kämpfer H, Wetzler C, Pfeilschifter J. Nitric oxide drives skin repair: novel functions of an established mediator. Kidney Int 2002;61(3):882-888 (Pubitemid 34175456)
85. Witte MB, Barbul A. Role of nitric oxide in wound repair. Am J Surg 2002;183(4):406-412 (Pubitemid 34442505)
86. Ziche M, Morbidelli l, Masini E, et al. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest 1994;94(5):2036-2044 (Pubitemid 24348244)
87. Papapetropoulos A, García-Cardeña G, Madri JA, Sessa WC. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 1997;100(12):3131-3139 (Pubitemid 28022851)
88. Frank S, Stallmeyer B, Kämpfer H, et al. Nitric oxide triggers enhanced induction of vascular endothelial growth factor expression in cultured keratinocytes (HaCaT) and during cutaneous wound repair. FASEB J 1999;13(14):2002-14
89. Schaffer MR, Efron PA, Thornton FJ, et al. Nitric oxide, an autocrine regulator of wound fibroblast synthetic function. J Immunol 1997;158(5):2375- 2381 (Pubitemid 127470024)
90. Noiri E, Peresleni T, Srivastava N, et al. Nitric oxide is necessary for a switch from stationary to locomoting phenotype in epithelial cells. Am J Physiol 1996;270(3 Pt 1):C794-802 (Pubitemid 126830968)
91. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414(6865):813-820 (Pubitemid 34000785)
92. Cosentino F, Eto M, De Paolis P, et al. High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells: role of protein kinase C and reactive oxygen species. Circulation 2003;107(7):1017-1023 (Pubitemid 36258726)
93. Guzik TJ, Mussa S, Gastaldi D, et al. Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 2002;105(14):1656-1662 (Pubitemid 34298608)
94. Luo JD, Wang YY, Fu Wl, et al. Gene therapy of endothelial nitric oxide synthase and manganese superoxide dismutase restores delayed wound healing in type 1 diabetic mice. Circulation 2004;110(16):2484-2493
95. Yamasaki K, Edington HD, McClosky C, et al. Reversal of impaired wound repair in iNOS-deficient mice by topical adenoviral-mediated iNOS gene transfer. J Clin Invest 1998;101(5):967-971 (Pubitemid 28125274)
96. Breen A, Dockery P, O'Brien T, Pandit A. Fibrin scaffold promotes adenoviral gene transfer and controlled vector delivery. J Biomed Mater Res A 2009;89A:876-884
97. Burnett Al, Nelson RJ, Calvin DC, et al. Nitric oxide-dependent penile erection in mice lacking neuronal nitric oxide synthase. Mol Med 1996;2(3):288-296 (Pubitemid 26265079)
98. Moore CR, Wang R. Pathophysiology and treatment of diabetic erectile dysfunction. Asian J Androl 2006;8(6):675-684 (Pubitemid 44869615)
99. Gonzalez-Cadavid NF, Rajfer J. Molecular pathophysiology and gene therapy of aging-related erectile dysfunction. Exp Gerontol 2004;39(11-12):1705-1712 (Pubitemid 39576140)
100. Gonzalez-Cadavid NF, Rajfer J. Therapy of erectile dysfunction: potential future treatments. Endocrine 2004;23(2-3):167-176 (Pubitemid 39140230)
101. Chancellor MB, Tirney S, Mattes CE, et al. Nitric oxide synthase gene transfer for erectile dysfunction in a rat model. BJU Int 2003;91(7):691-696 (Pubitemid 36583746)
102. Bivalacqua TJ, Usta MF, Champion HC, et al. Effect of combination endothelial nitric oxide synthase gene therapy and sildenafil on erectile function in diabetic rats. Int J Impot Res 2004;16(1):21-29 (Pubitemid 38401555)
103. Champion HC, Bivalacqua TJ, Hyman Al, et al. Gene transfer of endothelial nitric oxide synthase to the penis augments erectile responses in the aged rat. Proc Natl Acad Sci USA 1999;96(20):11648-11652 (Pubitemid 29487435)
104. Bivalacqua TJ, Champion HC, Mehta YS, et al. Adenoviral gene transfer of endothelial nitric oxide synthase (eNOS) to the penis improves age-related erectile dysfunction in the rat. Int J Impot Res 2000;12(Suppl 3):S8-17 (Pubitemid 32049653)
105. Bivalacqua TJ, Deng W, Kendirci M, et al. Mesenchymal stem cells alone or ex vivo gene modified with endothelial nitric oxide synthase reverse age-associated erectile dysfunction. Am J Physiol Heart Circ Physiol 2007;292(3):H1278-90 (Pubitemid 46377115)
106. Elrod JW, Duranski MR, Langston W, et al. eNOS gene therapy exacerbates hepatic ischemia-reperfusion injury in diabetes: a role for eNOS uncoupling. Circ Res 2006;99(1):78-85
107. Palmer DJ, Ng P. Helper-dependent adenoviral vectors for gene therapy. Hum Gene Ther 2005;16(1):1-16 (Pubitemid 40250327)